Cargando…

Chitosan Nanoparticles in Atherosclerosis—Development to Preclinical Testing

Chitosan is a natural biopolymer that is present in an abundant supply in sources such as crustacean shells, mushrooms, and insect exoskeletons. It can be used to make a variety of types of drug formulations and is generally safe to use in vivo; plus, it has inherent cholesterol-reducing properties....

Descripción completa

Detalles Bibliográficos
Autores principales: Sriamornsak, Pornsak, Dass, Crispin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145436/
https://www.ncbi.nlm.nih.gov/pubmed/35631521
http://dx.doi.org/10.3390/pharmaceutics14050935
_version_ 1784716315344240640
author Sriamornsak, Pornsak
Dass, Crispin R.
author_facet Sriamornsak, Pornsak
Dass, Crispin R.
author_sort Sriamornsak, Pornsak
collection PubMed
description Chitosan is a natural biopolymer that is present in an abundant supply in sources such as crustacean shells, mushrooms, and insect exoskeletons. It can be used to make a variety of types of drug formulations and is generally safe to use in vivo; plus, it has inherent cholesterol-reducing properties. While an abundance of papers has tested this biopolymer in nanoparticles in cancer and diabetes research, there is a lag of usage, and hence the paucity of information, in the area of cardiovascular research, specifically in atherosclerosis, the topic of this review. This review highlights some of the deficiencies in this niche area of research, examines the range of chitosan nanoparticles that have been researched to date, and proposes several ways forward to advance this field. Nanoparticles used for both diagnostic and therapeutic purposes are reviewed, with a discussion on how these nanoparticles could be better researched in future and what lays ahead as the field potentially moves towards clinical trials in future.
format Online
Article
Text
id pubmed-9145436
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91454362022-05-29 Chitosan Nanoparticles in Atherosclerosis—Development to Preclinical Testing Sriamornsak, Pornsak Dass, Crispin R. Pharmaceutics Review Chitosan is a natural biopolymer that is present in an abundant supply in sources such as crustacean shells, mushrooms, and insect exoskeletons. It can be used to make a variety of types of drug formulations and is generally safe to use in vivo; plus, it has inherent cholesterol-reducing properties. While an abundance of papers has tested this biopolymer in nanoparticles in cancer and diabetes research, there is a lag of usage, and hence the paucity of information, in the area of cardiovascular research, specifically in atherosclerosis, the topic of this review. This review highlights some of the deficiencies in this niche area of research, examines the range of chitosan nanoparticles that have been researched to date, and proposes several ways forward to advance this field. Nanoparticles used for both diagnostic and therapeutic purposes are reviewed, with a discussion on how these nanoparticles could be better researched in future and what lays ahead as the field potentially moves towards clinical trials in future. MDPI 2022-04-25 /pmc/articles/PMC9145436/ /pubmed/35631521 http://dx.doi.org/10.3390/pharmaceutics14050935 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sriamornsak, Pornsak
Dass, Crispin R.
Chitosan Nanoparticles in Atherosclerosis—Development to Preclinical Testing
title Chitosan Nanoparticles in Atherosclerosis—Development to Preclinical Testing
title_full Chitosan Nanoparticles in Atherosclerosis—Development to Preclinical Testing
title_fullStr Chitosan Nanoparticles in Atherosclerosis—Development to Preclinical Testing
title_full_unstemmed Chitosan Nanoparticles in Atherosclerosis—Development to Preclinical Testing
title_short Chitosan Nanoparticles in Atherosclerosis—Development to Preclinical Testing
title_sort chitosan nanoparticles in atherosclerosis—development to preclinical testing
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145436/
https://www.ncbi.nlm.nih.gov/pubmed/35631521
http://dx.doi.org/10.3390/pharmaceutics14050935
work_keys_str_mv AT sriamornsakpornsak chitosannanoparticlesinatherosclerosisdevelopmenttopreclinicaltesting
AT dasscrispinr chitosannanoparticlesinatherosclerosisdevelopmenttopreclinicaltesting